EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.
EMT inhibitor-1 (C19) is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities, inhibiting cancer cell migration, proliferation, and resistance to doxorubicin in vitro[1].
EMT inhibitor-1 (C19) exerts strong antitumor activity in a mouse tumor model. Mechanistically, EMT inhibitor-1 induces GSK3-β-mediated degradation of the Hippo transducer TAZ, through activation of the Hippo kinases Mst/Lats and the tumor suppressor kinase AMPK upstream of the degradation complex[1].
[1]. Basu D, et al. Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways. Mol Cancer Ther. 2014 Jun;13(6):1457-67.